Compare TK & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | ALVO |
|---|---|---|
| Founded | 1973 | 2013 |
| Country | Bermuda | Luxembourg |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 925.8M | 1.0B |
| IPO Year | 1995 | 2021 |
| Metric | TK | ALVO |
|---|---|---|
| Price | $12.93 | $4.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 498.3K | ★ 1.0M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 15.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | ★ $13.43 | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $2.94 |
| 52 Week High | $14.38 | $9.25 |
| Indicator | TK | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.09 | 71.99 |
| Support Level | $12.09 | $4.67 |
| Resistance Level | $13.09 | $5.46 |
| Average True Range (ATR) | 0.48 | 0.28 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 70.04 | 72.87 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.